drugset / Trial / NCT02749526
Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial
NaSingle-groupOpen-labelTreatment
Summary
Endostar ® (recombinant human endostatin) continuous intravenous infusion combined with mPFC neoadjuvant treatment of esophageal cancer arm, Ⅱ single-center clinical trial.
Timeline
- Start
- 2016-04
- Primary completion
- 2018-12
- Completion
- 2018-12
Outcome
Outcome not reported
Stopped (Enrollment): “low accrual rate”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Endostar | Protein / enzyme biologic | 30 mg | Intravenous |
| Background | Cisplatin | Other / unclassified | 25 mg/m2 | — |
| Background | Gimeracil | Small molecule | — | — |
| Background | Liposo | Unknown | 135 mg/m2 | — |
| Background | Tegafur | Unknown | 40 mg | — |
| Background | oteracil | Small molecule | — | — |